Gilead Sciences’ oral drug emvistegrast produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis. The Phase 2 trial tested a daily 200 mg dose for 12 weeks, delivering a statistically significant result above analysts’ expectations.